Compare AstraZeneca plc (AZN) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? AstraZeneca plc trades at $158.76 (market cap $248.14B), while iShares 1 3 Year Treasury Bond ETF trades at $81.94. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals.
| AZN | SHY | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Fixed Income |
52-Week High | $209.48 | $83.18 |
52-Week Low | $147.06 | $81.77 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
SHY (iShares 1-3 Year Treasury Bond ETF) trades at $81.94 with minimal daily movement (+0.1%). The technical picture shows bearish momentum with moving averages signaling caution, though oscillators remain neutral. Recent institutional activity indicates growing interest, with Barry Investment Advisors increasing their position by 48.1% in Q2 2026. Treasury yield fluctuations and inflation data remain key drivers for this short-term bond ETF.
Outlook remains tied to Federal Reserve policy and inflation trends. The ETF offers stability with regular dividends but faces headwinds from rising yields. Investment opportunity lies in capital preservation during market volatility, though rising rates could pressure short-term bond prices. Key risks include interest rate sensitivity and macroeconomic policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
